PRAX Quote, Financials, Valuation and Earnings

DocGo has a net margin of -786.27% compared to Praxis Precision Medicines's net margin of -9.79%. Praxis Precision Medicines's return on equity of -59.11% beat DocGo's return on equity of -0.2%.

Praxis Precision Medicines has a consensus price target of $97.67, signalling upside risk potential of 146.01%. On the other hand DocGo has an analysts' consensus of $3.05 which suggests that it could grow by 119.41%. Given that Praxis Precision Medicines has higher upside potential than DocGo, analysts believe Praxis Precision Medicines is more attractive than DocGo.

Praxis Precision Medicines has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison DocGo has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Praxis Precision Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DocGo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines pays -- of its earnings as a dividend. DocGo pays out -- of its earnings as a dividend.

Praxis Precision Medicines quarterly revenues are $7.5M, which are smaller than DocGo quarterly revenues of $96M. Praxis Precision Medicines's net income of -$69.3M is lower than DocGo's net income of -$9.4M. Notably, Praxis Precision Medicines's price-to-earnings ratio is -- while DocGo's PE ratio is 8.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines is 91.39x versus 0.29x for DocGo. Usually stocks with elevated PS ratios are considered overvalued.

IGM Biosciences has a net margin of -786.27% compared to Praxis Precision Medicines's net margin of -10599.6%. Praxis Precision Medicines's return on equity of -59.11% beat IGM Biosciences's return on equity of -241.68%.

Praxis Precision Medicines has a consensus price target of $97.67, signalling upside risk potential of 146.01%. On the other hand IGM Biosciences has an analysts' consensus of $1.88 which suggests that it could grow by 51.21%. Given that Praxis Precision Medicines has higher upside potential than IGM Biosciences, analysts believe Praxis Precision Medicines is more attractive than IGM Biosciences.

Praxis Precision Medicines has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGM Biosciences has a beta of 0.610, suggesting its less volatile than the S&P 500 by 38.975%.

Praxis Precision Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGM Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines pays -- of its earnings as a dividend. IGM Biosciences pays out -- of its earnings as a dividend.

Praxis Precision Medicines quarterly revenues are $7.5M, which are larger than IGM Biosciences quarterly revenues of $499K. Praxis Precision Medicines's net income of -$69.3M is lower than IGM Biosciences's net income of -$52.9M. Notably, Praxis Precision Medicines's price-to-earnings ratio is -- while IGM Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines is 91.39x versus 28.11x for IGM Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

Intellia Therapeutics has a net margin of -786.27% compared to Praxis Precision Medicines's net margin of -687.61%. Praxis Precision Medicines's return on equity of -59.11% beat Intellia Therapeutics's return on equity of -56.9%.

Praxis Precision Medicines has a consensus price target of $97.67, signalling upside risk potential of 146.01%. On the other hand Intellia Therapeutics has an analysts' consensus of $40.30 which suggests that it could grow by 316.72%. Given that Intellia Therapeutics has higher upside potential than Praxis Precision Medicines, analysts believe Intellia Therapeutics is more attractive than Praxis Precision Medicines.

Praxis Precision Medicines has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Intellia Therapeutics has a beta of 2.332, suggesting its more volatile than the S&P 500 by 133.227%.

Praxis Precision Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines pays -- of its earnings as a dividend. Intellia Therapeutics pays out -- of its earnings as a dividend.

Praxis Precision Medicines quarterly revenues are $7.5M, which are smaller than Intellia Therapeutics quarterly revenues of $16.6M. Praxis Precision Medicines's net income of -$69.3M is higher than Intellia Therapeutics's net income of -$114.3M. Notably, Praxis Precision Medicines's price-to-earnings ratio is -- while Intellia Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines is 91.39x versus 21.40x for Intellia Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Zevra Therapeutics has a net margin of -786.27% compared to Praxis Precision Medicines's net margin of -15.19%. Praxis Precision Medicines's return on equity of -59.11% beat Zevra Therapeutics's return on equity of -198.46%.

Praxis Precision Medicines has a consensus price target of $97.67, signalling upside risk potential of 146.01%. On the other hand Zevra Therapeutics has an analysts' consensus of $21.50 which suggests that it could grow by 141.3%. Given that Praxis Precision Medicines has higher upside potential than Zevra Therapeutics, analysts believe Praxis Precision Medicines is more attractive than Zevra Therapeutics.

Praxis Precision Medicines has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Zevra Therapeutics has a beta of 1.870, suggesting its more volatile than the S&P 500 by 87.041%.

Praxis Precision Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zevra Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines pays -- of its earnings as a dividend. Zevra Therapeutics pays out -- of its earnings as a dividend.

Praxis Precision Medicines quarterly revenues are $7.5M, which are smaller than Zevra Therapeutics quarterly revenues of $20.4M. Praxis Precision Medicines's net income of -$69.3M is lower than Zevra Therapeutics's net income of -$3.1M. Notably, Praxis Precision Medicines's price-to-earnings ratio is -- while Zevra Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines is 91.39x versus 10.83x for Zevra Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.